Cosmo Pharmaceuticals N.V., NL001183293626.05.2023 - 17:34:42
Cosmo Pharmaceuticals? Shareholders approve all Agenda Items at Annual General Meeting
Contact Hazel Winchester, Head of Investor Relations Cosmo Pharmaceuticals N.V.?? ??? ??? ? Tel: +353 1 817 03 firstname.lastname@example.org
Disclaimer Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
End of Media ReleaseLanguage: English Company: Cosmo Pharmaceuticals N.V. Riverside 2, Sir John Rogerson?s Dublin 2 Dublin
Ireland Phone: + 353 1 817 0370 E-mail: email@example.com Internet: https://www.cosmopharma.com/ ISIN: NL0011832936 Listed: SIX Swiss Exchange EQS News ID: 1643475 ? End of News EQS News Service